| 摘要: |
| 目的 基于真实世界临床数据,比较贝伐珠单抗原研药(安维汀)与生物类似药(安可达)二线治疗非鳞非小细胞肺癌的有效性和安全性,为临床用药选择提供参考。方法 回顾性分析2019年1月1日至2021年1月31日山东大学附属威海市立医院收治的82 例接受贝伐珠单抗注射液(安维汀)或(安可达)的IV期非鳞非小细胞肺癌患者的病历资料,采用Kaplan-Meier法进行单因素生存分析、采用χ2 检验进行安维汀组及安可达组临床及治疗特征比较、近期疗效及不良反应比较、Log-rank检验进行组间差异比较、Cox回归法进行多因素预后分析。结果 2年OS为63.3%,2年PFS为60.0%。安维汀组:ORR为33.3%,DCR为87.5%;安可达组:ORR为27.6%,DCR为96.6%。两组的DCR(疾病控制率)和ORR(客观缓解率)差异无统计学意义(P=0.147*;χ2 =0.271,P=0.603)。安维汀组较安可达组PFS(χ2 =0.022,P=0.883)和OS(χ2 =0.041,P=0.840)差异均无统计学意义。两组临床及治疗特征均未显示安维汀组优于安可达组。两组不良反应差异无统计学意义(P>0.05)。Cox法多因素分析显示:未脑转移是影响OS(HR=0.446,P=0.042)的独立保护因素。结论 安维汀组较安可达组DCR、ORR、PFS、OS和不良反应差异均无统计学意义。未脑转移是影响OS(HR=0.446,P=0.042)的独立保护因素。 |
| 关键词: 非鳞非小细胞肺癌 安维汀 安可达 不良反应 |
| DOI:10.13506/j.cnki.jpr.2026.06.014 |
| 基金项目:2021年度山东省医学会临床科研资金项目(No.YXH2022ZX02054) |
|
收稿日期:2026-03-20
修回日期:2026-04-14
|
|
| Real world study and comprehensive clinical evaluation of bevacizumab second-line treatment for non squamous non-small cell lung cancer |
| WANG Bing1,WANG Yuting1,HUANG Huixuan2,TANG Huaying1,CUI Yingjie1,LI Yuhui1,LENG Jiawei3 |
| (1.Department of Pharmacy,Weihai Municipal Hospital, Cheeloo College of Medicine, Shandong University, Weihai 264200, China;2.Nursing Department,Weihai Municipal Hospital, Cheeloo College of Medicine, Shandong University, Weihai 264200,China;3.Shandong Institute for Food and Drug Inspection and Research,Jinan 250101,China) |
| Abstract: |
| Objective To compare the efficacy and safety of the original bevacizumab (Avastin) and its biosimilar (Ankeda) in the second-line treatment of non-squamous non-small cell lung cancer (NSCLC) based on real-world clinical data, and to provide evidence for clinical decision-making.Methods The clinical data of 82 patients with non-squamous non-small cell lung cancer who received bevacizumab injection (Avastin) or (Ankeda) in Weihai Municipal Hospital Affiliated to Shandong University from January 1, 2019 to January 31, 2021 were retrospectively analyzed. Kaplan-Meier method was used for univariate survival analysis, χ2 test was used to compare the clinical and treatment characteristics, short-term efficacy and adverse reactions between the two groups, Log-rank test was used to compare the differences between the two groups, and Cox regression method was used for multivariate prognostic analysis.Results The 2-year OS and PFS were 63.3% and 60.0%, respectively. In the Avastin group: ORR was 33.3%, DCR was 87.5%; In the Anketa group, ORR was 27.6% and DCR was 96.6%. There was no significant difference in DCR (disease control rate) and ORR (objective response rate) between the two groups (P=0.147*; χ2=0.271, P=0.603). There were no significant differences in PFS (χ2=0.022, P=0.883) and OS (χ2=0.041, P=0.840) between Avastin group and Anketa group. The clinical and treatment characteristics of the two groups did not show that the Avastin group was superior to the Anketa group. There was no significant difference in adverse reactions between the two groups (P>0.05). Cox multivariate analysis showed that no brain metastasis was an independent protective factor for OS (HR=0.446, P=0.042).Conclusion There were no significant differences in DCR, ORR, PFS and OS between the two groups. There was no significant difference in adverse reactions between the two groups.No brain metastasis was an independent protective factor for OS. |
| Key words: Non-squamous non-small cell lung cancer Avastin Ankeda Adverse reactions |